45 307

Cited 0 times in

Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.

Authors
Kim, YH; Jung, EM; Lee, TJ; Kim, SH; Choi, YH; Park, JW; Choi, KS; Kwon, TK
Citation
Free radical biology & medicine, 44(6):1055-1068, 2008
Journal Title
Free radical biology & medicine
ISSN
0891-58491873-4596
Abstract
Death receptor 5 (DR5/TRAIL-R2) is an apoptosis-inducing membrane receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In this study, we show that rosiglitazone sensitizes human renal cancer cells to TRAIL-mediated apoptosis, but not normal human mesangial cells. Furthermore, because rosiglitazone-enhanced TRAIL-mediated apoptosis is induced in various types of cancer cells but is not interrupted by Bcl-2 overexpression, this combinatory treatment may provide an attractive strategy for cancer treatment. We found that treatment with rosiglitazone significantly induces DR5 expression at both its mRNA and its protein levels, accompanying the generation of reactive oxygen species (ROS). Both treatment with DR5/Fc chimeric protein and silencing of DR5 expression using small interfering RNAs attenuated rosiglitazone plus TRAIL-induced apoptosis, showing the critical role of DR5 in this cell death. Pretreatment with GSH significantly inhibited rosiglitazone-induced DR5 up-regulation and the cell death induced by the combined treatment with rosiglitazone and TRAIL, suggesting that ROS mediate rosiglitazone-induced DR5 up-regulation, contributing to TRAIL-mediated apoptosis. However, both DR5 up-regulation and sensitization of TRAIL-mediated apoptosis induced by rosiglitazone are likely PPARgamma-independent, because a dominant-negative mutant of PPARgamma and a potent PPARgamma inhibitor, GW9662, failed to block DR5 induction and apoptosis. Interestingly, we also found that rosiglitazone treatment induced down-regulation of cellular FLICE-inhibitory protein (c-FLIPs), and ectopic expression of c-FLIPs attenuated rosiglitazone plus TRAIL-mediated apoptosis, demonstrating the involvement of c-FLIPs in this apoptosis. Taken together, the results of this study demonstrate that rosiglitazone enhances TRAIL-induced apoptosis in various cancer cells by ROS-mediated DR5 up-regulation and down-regulation of c-FLIPs.
MeSH terms
Antineoplastic Agents/pharmacology*Apoptosis/drug effects*Blotting, WesternCASP8 and FADD-Like Apoptosis Regulating Protein/drug effects*CASP8 and FADD-Like Apoptosis Regulating Protein/metabolismCell LineDown-RegulationFlow CytometryHumansRNA InterferenceReactive Oxygen Species/metabolismReceptors, TNF-Related Apoptosis-Inducing Ligand/drug effects*Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolismReverse Transcriptase Polymerase Chain ReactionTNF-Related Apoptosis-Inducing Ligand/drug effects*TNF-Related Apoptosis-Inducing Ligand/metabolismThiazolidinediones/pharmacology*TransfectionUp-Regulation
DOI
10.1016/j.freeradbiomed.2007.12.001
PMID
18164688
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Biochemistry & Molecular Biology
AJOU Authors
최, 경숙
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse